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Prescription Drug Manufacturer Attempts to 
Prevent Abuse of Controlled Substances 
Amanda R. Hoersten, a fourth-year pharmacy student from Delphos, Ohio; Nathaniel Hedrick, a fourth-year pharmacy student from Brecksville, 
Ohio; Lacey Shumate, a fifth-year pharmacy student from Bucyrus, Ohio; H. Paige Stewart, a fifth-year pharmacy student from Centerburg, Ohio; 
Caitlin Swann, a fifth-year pharmacy student from Strongsville, Ohio; Michael Milks, BSPh '76, Ph.D., R.Ph, professor of pharmacology 
This knowledge-based activity is targeted for all pharmacists and is 
acceptable for 1.0 hour (0.1 CEU) of continuing education credit. This 
course requires completion of the program evaluation and at least a 
70 percent grade on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-11-024-H04-P 
Objectives: 
After completion of this program, the reader should be able to: 
1. Identify ways in which manufacturers can prevent abuse of pre-
scription drugs 
2. Distinguish between the requirements established by the FDA for 
generic vs. brand name drug manufacturers 
3. Describe how a manufacturer is already making strides to provide 
tamper-resistant dosage forms for highly abused drugs 
4. List ways in which pharmacists can play an important role in deter-
ring prescription drug abuse 
Abstract 
In the United States, prescription drug abuse is on the rise. This 
trend has impacted the makers of OxyContin®, as well as the 
manufacturers of other controlled substances, to reevaluate how 
they formulate their products, resulting in medications that are more 
difficult to abuse. These abuse-deterrent formulations utilize physi-
cal, chemical and aversion barriers, specific delivery systems, and 
prodrug technology to prevent abuse. Additionally, some manufac-
turers have implemented the use of risk-management campaigns 
and education programs to reduce the misuse of their products. 
Working together with prescription drug manufacturers, pharmacists 
play an important role in preventing abuse and educating patients 
on the appropriate use of their prescriptions. 
Background 
OxyContin, produced by Purdue Pharma since 1995, is a controlled-
release narcotic analgesic indicated for moderate to severe pain. With 
dosage forms containing between 10 mg and 80 mg of oxycodone, 
OxyContin has become a significant target for abuse. Instead of using 
the medication as prescribed, abusers chew or crush the tablet and then 
swallow or snort the powder to release the drug as rapidly as possible. 
In some cases, abusers will combine the powder with water or other 
solvent and inject it intravenously to produce a heroin-like effect. It is this 
relative ease of administration, combined with its ease of accessibility, 
that has led to the increased instances of abuse. OxyContin is just one 
of many prescription drugs that demonstrate substance-abuse potential. 
Overall, there were 22,400 drug-overdose deaths in the U.S. in 2005, 
compared with 17,000 in 1999. Since 2006, adults between the ages of 
35 and 54 die more frequently from poisonings, including drug overdose, 
than from automobile accidents. Opioids were involved in 40 percent 
of all poisonings in 2006.1 Furthermore, in 2001, narcotic analgesics 
represented 14 percent of all drug-abuse related emergency room visits. 
Of these visits, there was a 41.4 percent increase from 1999 to 2001 in 
hydrocodone mentions and a 186.3 percent increase in oxycodone men-
tions. 2 These statistics demonstrate why more media attention has been 
placed on opioid abuse in recent years. This presents a very difficult situ-
ation for health care providers as well as patients with legitimate medical 
needs. Evidence demonstrates the need for prescribers to make decisions 
on whether a patient needs the drug for a legitimate reason or if they are 
simply seeking drugs to feed an addiction. Pharmacists must then make 
the same decision about dispensing the prescribed drug, often with even 
less information. Because of these implications, drug manufacturers are 
looking to decrease the abuse potential of certain drugs. 
Manufacturers attempt to prevent abuse 
To produce abuse-deterrent drugs, manufacturers have used several 
approaches.3 The first creates a physical barrier involving the outer shell 
or coating of a tablet, which can increase the hardness and make the drug 
more difficult to extract. Extended-release stimulants used for the treatment 
of attention deficit-hyperactivity disorder (ADHD), extended-release Oxy-
Contin, and Marinol™, a cannabinoid used as an antiemetic and appetite 
stimulant, all utilize this technique to prevent misuse of these compounds. 
The second approach used to prevent drug abuse is to create a chemical 
barrier. In this technique, an opioid is formulated with an antagonist, such as 
naloxone or naltrexone, which blocks and reverses the opioid's effects when 
present at a high dose. When used appropriately, these formulations provide 
only low systemic levels of antagonist, which have little effect. Also, if the oral 
dose is chewed to release the opioid for immediate effect, a larger dose of 
the antagonist is released, blocking the euphoric effect of the opioid. More 
importantly, if an attempt is made to abuse this combination by injection, 
a substantial amount of the antagonist is delivered into systemic circula-
tion, thereby interfering with the abuser's intended euphoria. Suboxone®, 
used to treat opioid dependence, utilizes this technology by combining 
buprenorphine with naltrexone along with other physical barriers, which 
makes extraction difficult and time-consuming. 
Creating an aversion barrier is another way to deter abuse. This tech-
nique is similar to a chemical barrier; however, the chemical combined 
with the opioid is used to produce unpleasant effects when taken in 
excessive amounts. The prototypic drug of this group is Lomotil™, an 
antidiarrheal containing diphenoxylate and atropine, an anticholinergic 
drug with objectionable side effects. A delivery system barrier combines 
chemical and physical deterrents with a novel drug release design, as 
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seen in controlled-release Concerta®, has been found to have lower 
abuse levels than immediate-release forms of methylphenidate. 
Lastly, the application of prodrug technology is utilized to deter prescrip-
tion drug abuse. Prodrugs require absorption in the gastrointestinal 
tract, and then bioactivation into the active form of the drug occurs. Uti-
lizing this technology enables manufacturers to produce drugs that can-
not be abused by chewing, snorting or injection. Vyvanse, a controlled 
substance used to treat ADHD, utilizes prodrug technology. Using these 
technologies alone or in combination gives manufacturers many options 
to help fight the war on prescription drug abuse. 
Implementing risk-management campaigns is another way manufac-
turers can regulate the use of their drugs.4 Risk management is often 
mandated for specific brand-name drug manufacturers by the FDA. Ex-
amples include programs for buprenorphine (Suboxone® and Subutex) 
and extended-release oxycodone (OxyContin). Interviewing patients, 
utilizing electronic prescription drug-tracking databases, interviewing 
treatment providers, and interviewing and educating physicians are 
important elements of a risk-management program. However, these 
programs vary in level of involvement. Some only require a medication 
guide to be dispensed with the medication, while others require the 
implementation of a communication plan and monitoring of elements to 
ensure safe use in addition to providing a medication guide.3 
While risk-management campaigns may be helpful in preventing drug 
abuse, the FDA does not require generic manufacturers to employ 
them. Generic manufacturers are only required to establish bioequiva-
lence and mail educational brochures out to prescribers. This poses 
a significant problem when trying to deter drug abuse considering 
generics are widely dispensed due to their lower costs. For example, 
70 percent of the extended-release oxycodone market is currently 
represented by generics. Additionally, generic companies do not have 
to conduct any post-marketing surveillance to pinpoint problems and 
provide risk prevention. With the use of hydrocodone and methadone 
increasing dramatically, there is no regulation to provide education to 
the prescribers or to identify problems.4 Furthermore, generic fentanyl 
patches exemplify why simply establishing bioequivalence between 
a brand and generic drug may not be enough.5 Original brand name 
fentanyl patches, Duragesic®, utilized a reservoir system to contain 
the drug in the patch. These patches were rarely abused because 
inconsistent levels of drug are obtained from them, often resulting 
in death. However, some generic fentanyl companies produced a 
product that utilized a matrix patch system, which requires a larger 
quantity of active drug to be contained in the patch, making it easier to 
abuse. To address this problem, the FDA could impose stricter guide-
lines on generic manufacturers of drugs with addictive properties. 
Another attempt by manufacturers to deter prescription drug abuse 
involves the application of education programs.6 Purdue Pharma, the 
maker of OxyContin, created a program in 2003, called "Painfully Obvi-
ous," geared toward preventing prescription drug abuse mainly among 
teenagers. This campaign sought to make parents and other adults 
aware of what is in their medicine cabinets and the abuse potential of 
prescription drugs within their own homes. In addition to creating this 
education program, Purdue Pharma provided funding to four state-wide 
prevention groups to create their own prevention strategies. 
The Road to Reformulation 
OxyContin's developer, Purdue Pharma, has recently pursued a new objec-
tive: to reduce the potential for abuse while maintaining the clinical benefits 
for the patients who need it.7To decrease abuse potential, Purdue Pharma 
investigated different methods of abuse. Their research revealed that, of 
the 1,368 patients from 2001 to 2004 who entered treatment for OxyContin 
abuse, 72 percent took the crushed tablet orally, 11 percent "snorted" or 
inhaled the powder after crushing, and 17 percent injected the powder after 
crushing and combining it with a solvent. Intranasal and IV formulations 
were found to be the most dangerous due to the rapid increase in drug blood 
levels. At the onset of reformulation, the FDA, along with Purdue Pharma, 
agreed to aim for a product that was both tamper-resistant and effective. 
The tamper-resistant characteristics were defined as a formulation that was 
resistant to physical crushing, physical milling and chemical extraction and 
had no increased dissolution in ethanol. The effective product characteristics 
were defined as a formulation that released the medication at a rate that was 
bioequivalent to the previous formulation, a process that was robust enough 
to undergo commercial manufacture, and a tablet that was chemically and 
physically stable over time. 
After pursuing several different platforms, Purdue Pharma settled on a 
polymer called Remoxy, which has three distinct characteristics. The first 
characteristic is that it is very resistant to crushing and breaking. Repeated 
hammer strikes to a tablet reduce it to a single deformed wafer and not a 
powder. Many abusers reported crushing the old formulation between two 
spoons before manipulating it further. The new formulation is too hard and 
simply cannot be crushed in this way. The second characteristic of the new 
polymer is that, when the tablet is broken, the fragments retain much of its 
controlled-release (CR) properties. This is important because most abusers 
try to first physically break down a tablet and then extract the pure drug 
from the drug/CR membrane complex. This is done using a wide array of 
solvents and is known as chemical extraction and can be divided into three 
subsets. These subsets are simple, which is done at room temperatures 
with readily available solvents, moderate, also done at room temperature 
but utilizing more complex and harder-to-obtain solvents, and advanced, 
which employs the use of heat, time and more toxic solvents. Often in 
advanced extraction, multiple solvents may be used. Physical crushing of 
the tablet without the use of solvent was found to rapidly release 91 percent 
of the dose in the old form and 20-49 percent in the new dose (Table 1). 
Additionally, 100 percent of the dose was released within five minutes using 
the old tablet. Using the new tablet, only 20 percent was released in the first 
frve minutes, with just over 40 percent released after 40 minutes. For simple 
extraction, five different solvents were used on both the old and new form of 
the tablet. The average percentage of drug released across all five solvents 
was found to be 87 percent for the old formulation and less than 23 percent 
in the new formulation. Moderate solvents were tested and found to release 
more than twice as much drug when used with the old formulation compared 
to the new one. Results were equally positive for the advanced extraction 
technique. The old formulation was found to release 1.5 to 3 times as much 
drug as the new formulation when tested with the same solvent. The third 
and final property that makes the new polymer so promising is that it forms 
a viscous gel when combined with any of the aforementioned solvents. This 
makes extraction of the drug for injection nearly impossible. A single insulin 
syringe could obtain 49-58 percent of the dose from a tablet that had been 
crushed and dissolved. The new formulation allowed for less than or equal 
to 4 percent to be extracted using the same process. 
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All of these changes reduce the abuse potential for OxyContin while main-
taining the same bioavailability for patients with legttimate medical needs. 
Despite these improvements, it is still important for health care providers to 
monitor and evaluate each patient before prescribing OxyContin.7 Accord-
ing to the Director of the Division of Anesthesia and Analgesia Products in 
the FDA's Center for Drug Evaluation and Research, "Although this new 
lormulation of OxyContin may provide only an incremental advantage over 
the current version of the drug, it is still a step in the right direction. Prescrib-
ers and patients need to know that its tamper-resistant properties are limited 
and need to carefully weigh the benefits and risks of using this medication 
to treat pain." The FDA also is requiring Purdue Pharma to conduct a post-
market survey to determine the effectiveness of the new formulation.8 
Table 1 Absorption of new vs old OxyContin formulatlons.8 
Physical Simple Moderate Advanced Insulin 
Crushing Solvents Solvents Solvents Syringe 
Old Formulation 91% 87% 96% 98% 49-58% 
-c 
~ 
"' Cl> 05 New Formulation 20-49% 23% 50% 60% <4% 0::: 
:.e 0 
Unfortunately, since the release of the OxyContin reformulation, current 
drug abusers have been working together to overcome the abuse-deter-
rent drug. A quick search on the Internet reveals thousands of message 
board posts over the last year discussing the change in formulation. 
Abusers are sharing tips, including recipes, techniques and pictures, 
on how to abuse the new formulation. Therefore, despite the manu-
facturer's attempt to deter abuse, it is still occurring. As a result, health 
care professionals, including pharmacists, need to take an active role in 
preventing prescription drug abuse. 
Pharmacists' Role in Preventing Abuse 
While manufacturing attempts to decrease the abuse of controlled 
substances is a major step forward, pharmacists are in a position to play 
an integral role in preventing drug abuse. Their unique knowledge base 
allows them to help prevent abuse by educating and providing aware-
ness of its prevalence and assisting those dependent on a drug.9 Before 
a pharmacist even dispenses a controlled substance, appropriateness of 
therapy must be assessed for each patient. A prescription drug-tracking 
database, Ohio's Automated Rx Reporting System (OARRS), may be 
utilized to check for drug-seeking behavior in patients who present to the 
pharmacy with a prescription for a controlled substance. A few charac-
teristics of drug-seeking behavior to watch for include seeing multiple 
prescribers, visiting many pharmacies and forging prescriptions. Once 
the appropriateness of the drug therapy is determined, a pharmacist's 
primary role in drug-abuse prevention is to educate the patient on the 
appropriate use of a controlled substance. Topics include informing 
the patient of its addictive properties, the possibility of dependency, 
and appropriate storage and disposal. If it is confirmed that a patient 
is abusing a prescription and wishes to seek help, the pharmacist is a 
valuable resource for referring patients to rehabilitation services. Ad-
ditionally, pharmacists can utilize resources at their disposal to improve 
their knowledge of substance abuse and to educate other health care 
providers on the topic.10 
Pharmacists can take a more intensive role by providing education and 
ensuring prevention through various programs.9 Participation in public 
substance-abuse education and prevention programs provided at grade 
schools, high schools, colleges, churches and civic organizations is en-
couraged. These programs should focus on the potential adverse health 
consequences due to the misuse of drugs. Pharmacists also can foster 
the development of pharmacy school curricula and pharmacy technician 
education on the topic of substance abuse. Additionally, professional 
associations should assume responsibility of advocacy, continuing edu-
cation and publication of pharmacist-driven research in the field. 10 
Conclusion 
Encouraging manufacturers to take a leadership role in the prevention 
of drug abuse is vital. By utilizing abuse-deterrent medication formula-
tions, as well as risk-management campaigns and education campaigns, 
health care providers can better care for their patients. Pharmacists, 
working together along with the rest of the health care team, play an 
imperative role in educating patients on the appropriate use of controlled 
medications. Informing patients of the risk associated with these medica-
tions in an effort to prevent future abuse will positively impact the war 
on prescription drug abuse and hopefully aid in the deterrence of this 
unsettling trend. 
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Assessment Questions 
1. Which is NOT a way in which manufacturers can prevent abuse of 
their medications? 
a. Formulating a drug with physical, chemical and/or aversion 
barriers 
b. Creating an immediate release formulation with high levels of 
active ingredient to ensure a patient gets the most benefit from 
the drug 
c. Establishing risk-management campaigns and mandating 
education programs to ensure safe use of a controlled substance 
d. Utilizing prodrug technology when creating a new drug 
2. Risk-management campaigns can include which of the following? 
a. Labeling of approved indications for the medication and listing 
cautions or warnings 
b. Interviewing patients and educating physicians on high-risk drugs 
c. Utilizing electronic prescription drug-tracking devices and 
dispensing a medication guide with the medication 
d. All of the above 
3. Which of the following is NOT true about generic manufacturers 
compared to brand name manufacturers? 
a. Generic manufacturers are held to the same strict guidelines 
in relation to risk management pertaining to prescription drug 
abuse as brand name companies. 
b. It is sufficient for generic manufacturers to establish bioequivalence 
between a brand and generic drug and mail educational 
brochures out to prescribers. 
c. Generic companies do not have to conduct any post-marketing 
surveillance to pinpoint problems. 
d. Both A and B 
4. Drug-seeking behavior that pharmacists should be aware of include: 
a. Seeing multiple prescribers 
b. Utilizing one pharmacy to get all medications 
c. Getting angry when a controlled substance is not in stock 
d. Two of the above 
5. Drug-abuse prevention is the main responsibility of 
a. Prescribers 
b. Manufacturers 
c. Pharmacists 
d. All of the above 
6. Which is NOT a role the pharmacist plays in preventing prescription 
drug abuse? 
a. Assess appropriateness of this pharmacotherapy for each patient 
b. Educate the patient on the appropriate use of a controlled 
medication 
c. Informing the patient of a drug's addictive properties and the 
possibility of dependency with the goal of deterring the patient 
from taking the medication 
d. If a patient is abusing a prescription drug and wishes to seek help, 
the pharmacist may recommend a program that will provide help 
7. Pharmacists can play a more active part in preventing drug abuse by 
participating in 
a. The development of pharmacy school curricula and pharmacy 
technician education on the topic of substance abuse 
b. Education and prevention programs provided at grade schools, 
high schools, colleges, churches and civic organizations 
c. Both A and B 
d. None of the above 
8. Which statement is FALSE? 
a. A pharmacist's primary role in drug-abuse prevention is to 
make sure the patient is provided a sufficient drug to alleviate 
all of their pain regardless of the dependence associated with it 
b. Professional associations should assume responsibility of 
advocacy, continuing education and publication of pharmacist-
driven research in the field to provide insight on prescription 
drug abuse 
c. Pharmacists can utilize resources at their disposal to improve 
their knowledge of substance abuse and to educate other 
health care providers on the topic 
d. Education and prevention programs should focus on the 
potential adverse health consequences due to the misuse of 
prescription drugs 
9. Which of the following methods is most commonly utilized to abuse 
OxyContin? 
a. Chewing the tablet 
b. Injecting the powder after combining it with a solvent 
c. Taking several doses of CR tablets at once 
d. Snorting the Powder 
10. Which of these characteristics is NOT present in the new OxyContin 
formulation? 
a. Crush resistance 
b. Fragments that retain some CR properties 
c. Viscous Gel formation when combined with a solvent 
d. Heat Resistance 
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